Manufacturing & Packaging

Location serves as the US flagship for company’s global pharma development network.

Project—which is expected to double plant’s distribution capacity—will be completed by end of Q3.

Complex to develop cGMP-compliant, commercial-scale plasmid DNA.

Companies to release variety of options for this sector.

Expansion expected to help tackle health issues at a faster rate, company says

Transaction expected to close early this year

Creates Cellular Origins in order to simplify the late-stage development process

North Carolina facility to manufacture Pfizer’s pipeline products

Nottingham location expected to be fully operational by the end of 2023

Platform is expected to streamline batch turnaround times

Acquisition of Texas facility to add 60,000 square feet of manufacturing space to company’s footprint

Provider will be CDMO’s primary material supplier in the lab, clinical, and production settings

Award given in recognition of CDMO’s commitment to promoting sustainable future

Phoenix location will be company’s first to focus on high-density microarrays for diagnostic and life science research

CDMO will be able to produce rAAV commercial grade product

Provides clientele with an augmented drug development solution

Provider’s regulatory affairs, pharmacovigilance services expected to help increase ABC’s portfolio

Collaboration aims to decrease environmental burden in the space

Lotte Biologics will assume facility ownership, as CDMO joins pharma space with the acquisition

With the new additions, CDMO expands its analytical testing and development services

Big Pharma to collaborate with researchers from A*STAR, along with Singapore universities

Will further boost CDMO’s injectable drug product platform

Can help facilitate digital identification of medications

Drug safety analysis to be conducted at Rockland, MD facility

Plant will be CDMO’s first standalone GMP and vaccine development manufacturing site in the country